Merit of an ursodeoxycholic acid clinical trial in COVID-19 patients

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characterized with cytokine storm syndrome that can cause severe and irreversible damage to organs leading to multi-organ failure and death. Therefore, it is critical to control both programmed cell death (apoptosis) and the hyper-immune inflammatory response in COVID-19 patients to reduce the rising morbidity and mortality. UDCA is an existing drug with proven safety profiles that can reduce inflammation and prevent cell death. National Geographic reported that, “China Promotes Bear Bile as Coronavirus Treatment”. Bear bile is rich in UDCA, comprising up to 40–50% of the total bile acid. UDCA is a logical and attainable replacement for bear bile that is available in pill form and merits clinical trial consideration.

Original languageEnglish (US)
Article number320
Pages (from-to)1-4
Number of pages4
JournalVaccines
Volume8
Issue number2
DOIs
StatePublished - Jun 2020

Bibliographical note

Funding Information:
The authors gratefully acknowledge the support provided for this project by NASA through grant NAG5-6410 (LTSA). P. J. G. acknowledges support through NASA contract NAS8-39073 (CXC). We thank the anonymous referee, Fred Hamann, Martin Elvis, and Smita Mathur for valuable comments. The data in this Letter are based on observations made with the NASA/ESA Hubble Space Telescope, obtained from the data archive at the Space Telescope Science Institute, which is operated by the Association of Universities for Research in Astronomy, Inc., under the NASA contract NAS 5-26555.

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • COVID-19
  • Clinical trial
  • Coronavirus
  • Cytokine storm
  • Ursodeoxycholic acid

Fingerprint

Dive into the research topics of 'Merit of an ursodeoxycholic acid clinical trial in COVID-19 patients'. Together they form a unique fingerprint.

Cite this